Skip to main content
PharmaMar cancer drug candidate licensed in Australia, Southeast Asia

PharmaMar's cancer drug candidate PM1183, or lurbinectedin, has been licensed to Specialized Therapeutics Asia for marketing in 12 Southeast Asian nations as well as New Zealand and Australia. Under the terms of the deal, PharmaMar will get an upfront payment and is eligible to receive payments tied to regulatory and sales milestones for the RNA polymerase II inhibitor.

Full Story: